Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.
from Medical Xpress - latest medical and health news stories https://ift.tt/m7TW1Un
